Alamar selects Abcam as a key provider of antibody content for its propriety NULISA technology platform FREMONT, Calif. and CAMBRIDGE, England, Jan. 4, 2022 /PRNewswire/ Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in.
Alamar Biosciences partners with Abcam to drive understanding of the human proteome
tarantobuonasera.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tarantobuonasera.it Daily Mail and Mail on Sunday newspapers.
VC Daily: Biotechs Seek New Skill Set From Scientists Entering Field
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Illumina Ventures Closes $325M Fund
finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.
Reports And Data: Proteomics Market Revenue Growth Riding On Personalized Medicine Trend: Reports and Data
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.